Progression to microalbuminuria in type 1 diabetes: development and validation of a prediction rule by Vergouwe, Y. et al.
ARTICLE
Progression to microalbuminuria in type 1 diabetes:
development and validation of a prediction rule
Y. Vergouwe & S. S. Soedamah-Muthu & J. Zgibor & N. Chaturvedi & C. Forsblom &
J. K. Snell-Bergeon & D. M. Maahs & P.-H. Groop & M. Rewers & T. J. Orchard &
J. H. Fuller & K. G. M. Moons
Received: 11 September 2009 /Accepted: 23 September 2009 /Published online: 4 November 2009
# The Author(s) 2009. This article is published with open access at Springerlink.com
Abstract
Aims/hypothesis Microalbuminuria is common in type 1
diabetes and is associated with an increased risk of renal
and cardiovascular disease. We aimed to develop and
validate a clinical prediction rule that estimates the absolute
risk of microalbuminuria.
Methods Data from the European Diabetes Prospective
Complications Study (n=1115) were used to develop the
prediction rule (development set). Multivariable logistic
regressionanalysiswasusedtoassessthe associationbetween
potential predictors and progression to microalbuminuria
within 7 years. The performance of the prediction rule was
assessed with calibration and discrimination (concordance
statistic [c-statistic]) measures. The rule was validated in
three other diabetes studies (Pittsburgh Epidemiology of
Diabetes Complications [EDC] study, Finnish Diabetic
Nephropathy [FinnDiane] study and Coronary Artery Calci-
fication in Type 1 Diabetes [CACTI] study).
Results Of patients in the development set, 13% were
microalbuminuric after 7 years. Glycosylated haemoglobin,
AER, WHR, BMI and ever smoking were found to be the
most important predictors. A high-risk group (n=87 [8%])
was identified with a risk of progression to microalbumi-
nuria of 32%. Predictions showed reasonable discriminative
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DOI 10.1007/s00125-009-1585-3ability, with c-statistic of 0.71. The rule showed good
calibration and discrimination in EDC, FinnDiane and
CACTI (c-statistic 0.71, 0.79 and 0.79, respectively).
Conclusions/interpretation We developed and validated a
clinical prediction rule that uses relatively easily obtainable
patient characteristics to predict microalbuminuria in
patients with type 1 diabetes. This rule can help clinicians
to decide on more frequent check-ups for patients at high
risk of microalbuminuria in order to prevent long-term
chronic complications.
Keywords Microalbuminuriarisk.Predictionmodel.
Progression.Type1diabetes
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Introduction
Microalbuminuria is common in type 1 diabetes. Of
patients with type 1 diabetes, 30 to 60% progress to
microalbuminuria within 10 to 20 years [1, 2]. Various risk
factors have been found for the progression to micro-
albuminuria including: hyperglycaemia, hyperlipidaemia,
(central) obesity, hypertension and smoking [2–5].
Patients with microalbuminuria have elevated risks of
diabetic renal disease [6, 7] and cardiovascular disease [8].
Timely prediction of progression to microalbuminuria in
patientswithtype 1diabetesisthereforeofmajor importance.
Accurate identification of patients at high risk of micro-
albuminuria at an early stage can guide disease management
in order to prevent further complications. Intervention in
high-risk patients may be beneficial, although data to support
this are inconclusive.
Prediction of microalbuminuria progression is rarely
studied [2, 5]. Only one prediction rule has been proposed
before [5]. This rule uses arbitrary dichotomisation of
various continuous predictor values (HbA1c and AER).
Further, selection of the predictors was based on a p value
of 0.05, which is considered conservative in prediction
modelling. Both strategies potentially lead to an optimistic
or overfitted prediction rule [9, 10]. Moreover, the
prediction rule was not validated in an independent sample.
Using state of the art methods in prediction modelling,
we therefore developed and externally validated a clinical
prediction rule for estimating risk of progression to micro-
albuminuria in patients with type 1 diabetes. We used data
from large prospective cohort studies of type 1 diabetes. The
rule was developed with data from the European Diabetes
Prospective Complications Study (EURODIAB PCS) [11]
and validated in US patients treated in a similar time period
(Pittsburgh Epidemiology of Diabetes Complications
[EDC]) study [1]. Since treatment policies have changed
over the years, we also studied the validity of the rule in
two more contemporary studies, i.e. the Finnish Diabetic
Nephropathy study (FinnDiane) [12] and the Coronary
Artery Calcification in Type 1 Diabetes study (CACTI) [13].
Methods
Patients We used data from the EURODIAB PCS to
develop the prediction rule (development set). Full details
of the design, methods and recruitment have been published
elsewhere [11]. Inbrief, the study was designedtoinvestigate
risks and determinantsofmicrovascular complications intype
1 diabetes patients. The EURODIAB PCS cohort included
patients from 31 centres in 16 European countries.
Type 1 diabetes was defined as a diagnosis made before
the age of 36 with continuous insulin treatment within
1 year of diagnosis. Patient measurements were taken at
baseline (1990–1991) and at 7 years follow-up (1997–
1999). Patients were included in the present analysis if they
had a normal AER, i.e. below 20 μg/min, at baseline and a
normal AER or microalbuminuria (AER between 20 and
200 μg/min) at follow-up.
We used data from three studies to externally validate the
prediction rule (validation sets): the EDC study, FinnDiane
and CACTI. The EDC study is a hospital-based incidence
cohort from the Children’s Hospital of Pittsburgh, USA, set
up to investigate risk factors for complications of these
patients [1]. After the baseline examination (1986–1988),
patients were re-examined biennially. The FinnDiane study
is a nationwide, multicentre study with the aim to identify
genetic and clinical risk factors for diabetic nephropathy in
type 1 diabetes [12]. Patients have been followed since the
baseline examination (1998). The CACTI study is a
prospective cohort study designed to assess risk factors
associated with the development and progression of
subclinical coronary artery disease [13]. Baseline examina-
tion was performed between 2000 and 2002. All three
studies are ongoing. For the present analysis, follow-up
measurements 7 years after inclusion were taken to assess
the development of microalbuminuria. The same inclusion
criteria were used as for the development set.
Outcome Microalbuminuria (yes/no) was determined
7 years after inclusion and defined as an AER between 20
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24 h urine samples was used for classification. Albumin
concentrations were assessed with an immunoturbidimetric
[14] method that included goat anti-human albumin antisera
(Sanofi Diagnostics Pasteur, Chaska, MN, USA) and
human serum albumin standards (ORHA 20/21 grade
HAS; Behring Diagnostics, Hoechst UK, Hounslow, UK).
Proteinuria due to urinary tract infection was excluded.
In the EDC study, an immuno-nephelometric method
was used [15] and the median AER was calculated on the
basis of three urine samples (24 h, overnight and 4 h post-
clinic) or the average AER if only two samples were
available. In the FinnDiane study, AER was calculated from
a single 24 h urine collection, which was measured by
immunoturbidimetry. The actual classification of patients
was based on two out of three consecutive urine samples. In
the CACTI study, AER was calculated from urinary albumin
measured using RIA in two timed overnight urine samples
with the results from the two nights being averaged.
Candidate predictors The patient characteristics available
in the EURODIAB PCS dataset were critically reviewed
using the literature and clinical expertise. The following
characteristics were considered to be possibly predictive for
microalbuminuria: age, sex, duration of diabetes, HbA1c,
AER, fasting triacylglycerol, non-HDL- and LDL-
cholesterol, WHR, BMI, pulse pressure, hypertension and
smoking. HbA1c was measured with an enzyme immunoas-
say using a monoclonal antibody. The HbA1c values
obtained were converted to DCCT values [16]. One 24 h
urine sample was analysed to determine the AER. Serum
lipids were measured with standard enzymatic methods.
Non-HDL-cholesterol was calculated as the total cholesterol
level minus the HDL level. Height, weight, and waist and
hip circumference were measured in a standardised way to
calculate BMI and WHR. Blood pressure was measured by a
random zero sphygmomanometer and the mean of two
measurements taken. Pulse pressure was calculated as
systolic minus diastolic pressure. Hypertension was defined
as a systolic pressure of 140 mmHg or more, a diastolic
pressure of 90 mmHg or more, or the current use of
blood-pressure-lowering medication. Smoking status was
dichotomised into ever vs never smokers.
Statistical analysis In the EURODIAB PCS, 355 patients
had values missing for one or more predictors. The average
percentage of missing values per predictor was 3%. We
imputed missing data using the linear-regression method
with addition of a random-error term (single imputation)
available in SPSS software (version 12.0; SPSS, Chicago,
IL, USA).
Logistic regression was used to estimate univariable and
multivariable regression coefficients, and odds ratios with
95% CIs for each predictor. The nature of the association
between continuous predictors and risk of microalbuminu-
ria was studied with restricted cubic splines with three
knots (two df). The restricted cubic splines were plotted and
approximated with simple transformations. The simplest
transformation is a linear term. Other possible transforma-
tions included the natural logarithm, square and square root.
A full multivariable model was fitted that included all
candidate predictors with chosen transformations. The
number of predictors was reduced with backward stepwise
selection. We applied Akaike’s information criterion [17]
for predictor selection, which corresponds to a p value of
0.157 for a predictor with one regression coefficient.
Interaction terms between predictors were assessed, but
not included because their predictive effects were very
limited. The regression coefficients in the final model were
multiplied with a shrinkage factor, which was estimated
with bootstrapping [9, 18]. Shrinkage is applied to obtain
accurate predictions for new patients; without shrinkage,
predictions are in general too extreme, resulting in low
predictions being too low and high predictions too high.
The described analytical strategy to develop the predic-
tion rule is in accordance with the current state of the art
[9]. The strategy aims to develop a prediction rule that can
provide accurate predictions for future patients rather than
predictions that are correct for patients of the development
dataset. Therefore, the selection of predictors in the model
is based on multivariable modelling only with a backward
selection procedure and liberal p value (0.157 in this study).
Use of higher p values results in inclusion of relatively
weakerpredictorsinthemodelatthecostofpossibleselection
of a nuisance variable. Such a model performs well in new
patients [19]. Further, the backward selection procedure
starts with a limited number of candidate predictors with
continuous variables studied in their original form (i.e.
continuously). Dichotomising or categorising continuous
variables may be seen as introducing an extreme form of
rounding, with an inevitable loss of information [20].
The final model with the shrunken regression coeffi-
cients was presented as a score chart to facilitate clinical
application. Scores were calculated by dividing the products
of regressioncoefficients and predictorvalues by the smallest
product. A constant was subtracted or added to rescale the
scores in positive integers. The sum scores were then related
to predicted risks.
The performance of the prediction rule was studied in
terms of calibration (i.e. agreement between predicted risks
and observed proportions of microalbuminuria) and discrim-
ination. Discrimination was expressed with a concordance
statistic (c-statistic), which is similar to the area under the
receiver-operating characteristic curve when dichotomous
outcomes are considered [21]. The performance was studied
in 100 bootstrap samples (internal validation) and in the
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CACTI studies (external validation). Internal validation
gives an impression of how much the performance of the
prediction rule may deteriorate when applied to a new
patient sample from the same population. External validation
indicates how generalisable the prediction rule is to similar
patients from other populations.
Results
Development of prediction rule The EURODIAB PCS
cohort contained 1,115 patients with normal AER at
baseline and normal AER or microalbuminuria at follow-
up. Microalbuminuria was found in 143 (13%) patients
after a mean follow-up of 7.3 years. The mean age at
baseline was 33 years, 49% of the patients were male and
mean duration of diabetes was 14 years (Table 1).
Table 2 shows the univariable associations of the studied
patient characteristics and progression to microalbuminuria.
Continuous predictor values for this table were dichotom-
ised at clinically relevant cut-offs or at the medians, in order
to show interpretable odds ratios. Note that the multivari-
able analysis was performed with the continuous variables.
Progression to microalbuminuria was associated with
HbA1c, AER, all lipids, WHR, BMI and smoking.
The multivariable analysis indicated that HbA1c, AER,
WHR, BMI and smoking were the strongest predictors
of progression to microalbuminuria (Table 3). The best
transformation for HbA1c was the natural logarithm
(Fig. 1a). As a consequence, this variable was transformed
into loge (HbA1c-value). Linear associations with risk of
microalbuminuria were observed for AER, WHR and BMI
(Fig. 1b–d). The regression coefficients in the final model
were multiplied with the estimated shrinkage factor of 0.88
(Table 3).
We distinguished four risk groups that were based on the
sum scores (Table 4). The observed proportions and mean
predicted risks were in good agreement across the four risk
groups. The two highest risk groups together (sum scores
16–20 and ≥21) contained 77% n ¼ 83 þ 27 ¼ 110 ðÞ of all
143 microalbuminuric patients of the EURODIAB PCS; the
low-risk group (sum scores 2–10) contained only 1% (n=2)
of microalbuminuric patients. The c-statistic was 0.71,
indicating reasonable discriminative ability. Internal valida-
tion reduced the c-statistic to 0.69 indicating minor
optimism in the modelling procedure.
External validation of the prediction rule The EDC patients
were slightly younger than patients of the development set
(mean age 26 years compared with 33 years). The
FinnDiane and CACTI patients were slightly older (36
Table 1 Characteristics of patients in the development and validation sets
EURODIAB PCS (1990–1991) EDC (1986–1988) FinnDiane (1998) CACTI (2000–2002)
Participants (n) 1,115 190 1,248 331
Age (years) 33 (9.6) 26 (8.1) 36 (12) 37 (9)
Male sex, n (%) 542 (49) 82 (43) 591 (47) 147 (44)
Diabetes duration (years) 14 (8.9) 18 (7.3) 16 (8.6) 23 (9)
HbA1c (%) 8.0 (1.7) 8.3 (1.3) 8.2 (1.4) 7.8 (1.2)
AER (μg/min)
a 8.2 (0.91–20) 8.5 (0.83–20) 5.2 (0.30–20) 5.0 (0.5–20)
Fasting triacylglycerol (mmol/l)
a 0.88 (0.30–5.1) 0.77 (0.35–4.8) 0.93 (0.32–10) 0.80 (0.30–4.1)
Non-HDL (mmol/l) 3.6 (1.0) 3.1 (0.72) 3.5 (0.91) 3.0 (0.80)
LDL (mmol/l) 3.2 (0.90) 2.7 (0.62) 3.0 (0.80) 2.5 (0.72)
WHR, men 0.88 (0.07) 0.86 (0.04) 0.89 (0.07) 0.86 (0.06)
WHR, women 0.79 (0.10) 0.77 (0.05) 0.80 (0.06) 0.78 (0.07)
BMI, men (kg/m
2) 24 (2.6) 23 (3.3) 25 (3.1) 26 (3.4)
BMI, women (kg/m
2) 23 (2.9) 24 (3.5) 25 (3.7) 26 (4.9)
Diastolic pressure (mmHg) 73 (11) 68 (8.7) 78 (9.0) 77 (8.4)
Systolic pressure (mmHg) 118 (15) 108 (11) 129 (16) 115 (13)
Pulse pressure (mmHg) 44 (12) 40 (9.0) 51 (13) 39 (11)
Hypertension, n (%) 148 (13) 2 (1) 176 (14) 107 (32)
Ever smoked, n (%) 498 (45) 52 (27) 507 (41) 65 (20)
Outcome at follow-up
Microalbuminuria, n (%) 143 (13) 34 (18) 96 (7.7) 20 (6.0)
Values are the mean (SD) unless otherwise noted
aMedian (range)
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n % n %
Age
<30 years 435 87 63 13
≥30 years 537 87 80 13 1.0 0.72–1.5
Sex
Men 469 86 73 14
Women 503 88 70 12 0.89 0.63–1.3
Duration
<15 years 610 87 91 13
≥15 years 362 87 52 13 1.0 0.67–1.4
HbA1c
<8.0% 558 92 52 8
≥8.0% 414 82 91 18 2.4 1.6–3.4
AER
<8 μg/min 491 91 46 9
≥8 μg/min 481 83 97 17 2.2 1.5–3.1
Fasting triacylglycerol
<1.0 mmol/l 643 90 75 10
≥1.0 mmol/l 329 83 68 17 1.8 1.2–2.5
Non-HDL
<3.5 mmol/l 498 90 56 10
≥3.5 mmol/l 474 84 87 16 1.6 1.1–2.3
LDL
<3.0 mmol/l 449 90 50 10
≥3.0 mmol/l 523 85 93 15 1.6 1.1–2.3
WHR
Men
<0.95 417 87 62 13
≥0.95 52 82 11 18 1.4 0.70–2.9
Women
<0.85 425 89 54 11
≥0.85 78 83 16 17 1.6 0.88–3.0
BMI
Men
<25 kg/m
2 347 89 43 11
≥25 kg/m
2 122 80 30 20 2.0 1.2–3.3
Women
<25 kg/m
2 389 89 49 11
≥25 kg/m
2 114 84 21 16 1.5 0.84–2.5
Pulse pressure
<40 mmHg 368 86 58 14
≥40 mmHg 604 88 85 12 0.89 0.62–1.3
Hypertension
No 844 87 123 13
Yes 128 86 20 14 1.1 0.65–1.8
Smoking
Never 550 89 67 11
Ever 422 85 76 15 1.5 1.0–2.1
Total 972 87 143 13
Table 2 Univariable associa-
tions of patient characteristics
assessed at baseline with
progression to microalbuminuria
258 Diabetologia (2010) 53:254–262and 37). Occurrence of hypertension varied between 1%
(EDC) and 32% for the validation sets, with 13% in the
development set. Progression to microalbuminuria occurred
in 18% (EDC), 8% (FinnDiane) and 6% (CACTI) of
patients (Table 1).
Most of the microalbuminuric patients were categorised
in one of the two groups with the highest risk: 27/34 (79%)
for EDC, 81/96 (84%) for FinnDiane and 16/20 (80%) for
CACTI (Table 4), which is similar to the results found in
the development set. The discriminative ability of the
prediction rule was similar to that in the development set
for the EDC patients with c-statistic=0.72. The discrimina-
tive ability was even better in the FinnDiane and CACTI
patients (c-statistic=0.79 in both).
The mean predicted risks in the two datasets with
recently treated patients (FinnDiane and CACTI) were
higher than the observed proportions of microalbuminuria
(13% predicted risk and 8% observed in FinnDiane, 11%
and 6% in CACTI). We adjusted the intercept of the
prediction rule in such a way that the mean predicted risk
agrees with the observed proportion of microalbuminuria
(intercept changes from −9.88 to −10.14).
Figure 2 shows a score chart that corresponds to the
adjusted prediction rule. The score chart facilitates calculation
of the predicted risk of microalbuminuria for an individual
patient who is currently treated. Values for continuous
predictors are given in small steps. An individual sum score
consists of the sum of all scores. The lower part of the figure
shows the predicted risks that correspond to the sum scores.
Discussion
We developed and validated a clinical prediction rule that
can be used to predict progression from normal AER to
microalbuminuria in type 1 diabetes patients. First, we
identified a series of predictors for the risk of progression to
microalbuminuria within a period of 7 years. The following
five characteristics predominantly contributed to prediction
in a multivariable logistic regression model: HbA1c, AER,
WHR, BMI and ever smoking. These predictors can be
relatively easily obtained by physical examination and
laboratory tests. External validation of the prediction rule
in three independent patient samples showed good
performance.
HbA1c and baseline AER have consistently been shown
to be important predictors of microalbuminuria [2–5, 22]
and were also included in a previous model developed by
Rossing and co-workers [5]. Smoking was also included in
both models. In contrast, BMI and WHR were included in
the present model, but were not considered in the
development of the Rossing model, which did, however,
include retinopathy. We found with the EURODIAB data
that the present model discriminated patients with micro-
albuminuria from those with normal AER better than the
Rossing model, which included retinopathy (c-statistics
0.69 and 0.65 respectively). A model that included the four
predictors of the Rossing model (HbA1c, AER, current
smoking and any retinopathy) fitted with the EURODIAB
PCS data showed a c-statistic of 0.66. The additive
predictive value for WHR in a model that already includes
BMI indicates that central obesity contains different
information than general obesity. This is confirmed by the
Table 3 Multivariable associations of selected predictors for progres-
sion to microalbuminuria
Predictor OR 95% CI β coefficient
a
HbA1c (%), transformed
b 1.26 1.09, 1.45 0.206
AER (μg/min) 1.09 1.07, 1.11 0.076
WHR, transformed
c 1.20 0.90, 1.61 0.163
BMI (kg/m
2) 1.07 1.03, 1.10 0.059
Ever smoking 1.40 1.16, 1.69 0.300
Intercept −9.883
c-statistic
d 0.71 0.69
aβ coefficients were multiplied by a shrinkage factor of 0.88 to
improve predictions in future patients
bLoge(HbA1c)×10
cWHR×10
dEstimated in the development set and corrected for optimism after
bootstrapping
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Fig. 1 Nature of the univariable associations of the continuous
predictors a HbA1c, b AER, c WHR and d BMI with the risk of
microalbuminuria. Continuous lines, restricted cubic splines with three
knots; dotted lines, the chosen transformations. Transformations: a
loge, b–d linear. The deviant scaling on y-axes corresponds to the
logodds or logit of microalbuminuria, which is the adequate scale to
study the shape of the association
Diabetologia (2010) 53:254–262 259relatively low correlation between WHR and BMI (Pearson
correlation r=0.21). The differences in effect of central and
general obesity have also been described for the risk of
cardiovascular events [23].
The predictors hyperglycaemia and central obesity are
part of the insulin resistance syndrome [24]. Insulin
resistance is also a risk factor for the development of
diabetic complications. We further studied the added value
of insulin sensitivity with the amount of fasting insulin (per
kg body weight). However, this factor did not have added
value in our model (p=0.53).
Continuous predictors are best included in a model as
such and not categorised [20]. In this way, all information is
used for the prediction. Continuous variables do not
necessarily have to be included as linear terms. We found
that logarithmic transformation of HbA1c predicts the risk
of microalbuminuria better than the frequently used linear
values. The nature of the relation between AER and risk of
microalbuminuria was linear, although a logarithmic trans-
formation of AER is frequently used [3, 5]. Apparently, a
logarithmic transformation of AER is only necessary to
estimate correct values of the mean and standard deviation,
given the skewed distribution of AER.
We studied the generalisability of our prediction rule
with respect to place (EDC), time (FinnDiane) and time and
place (CACTI). The US cohort (EDC) with patients treated
in the same time period as the patients from the
development set (the 1990s) showed similar discriminative
ability of the prediction rule (c-statistic=0.71 compared
with 0.69 in the development set). C-statistic values around
0.7 indicate reasonable discriminative ability for prognostic
models. Prediction of an event later in time (here 7 years) is
more difficult than prediction of an event shortly after the
baseline measurement. Furthermore, the predicted risks
were reasonably in agreement with the observed propor-
tions of microalbuminuria (Table 4).
It was particularly important to study the generalisability
of the prediction rule in time, since treatment of type 1
diabetes patients with normal AER has changed. Nowadays,
ACE inhibitors and statins are prescribed more frequently to
lower blood pressure and lipid plasma concentrations
respectively. The use of these medications has been shown
to affect the transition from normo- to microalbuminuria in
type 1 diabetes patients [25, 26], as was also apparent from
our data. The incidence of microalbuminuria was only 7.7%
in FinnDiane and 6.0% in CACTI compared with 13% in
the earlier development sample. Indeed, predicted risks were
too high for the patients from the FinnDiane and CACTI
studies. However, the model was well able to discriminate
Table 4 Observed proportions and predicted risks of microalbuminuria among four risk groups in the development set (EURODIAB PCS) and
validation sets (EDC, FinnDiane and CACTI)
Sum score EURODIAB PCS EDC FinnDiane CACTI
Observed
proportion
Mean
predicted
risk
Observed
proportion
Mean
predicted
risk
Observed
proportion
Mean
predicted
risk
Observed
proportion
Mean
predicted
risk
n/N %% n/N %% n/N %% n/N %%
2–10 2/73 3 3 0/5 0 4 1/61 2 4 1/22 5 4
11–15 31/470 7 8 7/88 8 8 14/564 3 8 3/196 2 8
16–20 83/485 17 16 22/83 27 15 47/509 9 15 12/93 13 15
≥21 27/87 31 32 5/14 36 31 34/114 30 32 4/20 20 31
Predictor   
HbA1c
Value: 
Score:
Albumin excretion rate (µg/min)  
Value:
Score:
Waist:hip ratio 
Value:
Score:
Body mass index (kg/m2)
Value:
Score:
Ever smoked                              
Value:
Score: 
Total sum score 
 
4     5      6     7     8      9    10    11   12 
0   1.5     3     5    6.5    8      9    10   11 
 
1     3      5     8    10    13   16   18    20 
0     1      2     3     4      5      6     7     8 
 
0.7   0.8    0.9    1.0    1.2  1.3    1.4 
  1       2       3       4       5       6       7 
 
 18     21   24      27     30      33 
  1       2       3       4       5       6 
 
No        Yes  
 0          2 
 
 
… 
 
 
… 
 
 
… 
 
 
… 
 
 
… 
 
 
… 
 
Total sumscore              6     8   10     12     14     16     18      20     22     24     26     28    30 
Risk of micro-                  
albuminuria (%)         1.5    2     3     4.5      6       9     14      19     25     32     43     54    63 
Fig. 2 Score chart to predict risk of microalbuminuria in patients with
type 1 diabetes. The scores are derived from the prediction rule that
contain the shrunken regression coefficients of the final model and
updated intercept: lp ¼  10:14 þ 0:21   loge HbA1c ðÞ þ 0:08 
AER þ 1:63   WHR þ 0:06   BMI þ 0:30   ever smoking,w h e r e
loge(HbA1c) is the natural logarithm of HbA1c, AER is expressed in
μg/min, BMI is expressed in kg/m
2 and ever-smoking is set at 1 if true
and 0 if false. Risk of microalbuminuria ¼ 1= 1 þ exp  lp ½  ðÞ .A
hypothetical patient with HbA1c of 6% (3 points), AER of 5 μg/min
(2 points), WHR of 0.9 (3 points), BMI of 24 (3 points) and who has
never smoked (0 points) has a sum score of 11, which corresponds to a
risk of 4%
260 Diabetologia (2010) 53:254–262between patients with and without microalbuminuria.
Therefore, a simple recalibration step was sufficient to
make the rule valid for recently treated patients.
The clinical implications of our study are that risk of
microalbuminuria can be established at an early stage and
patient management tailored to risk levels. We categorised
the patients into four risk groups with scores 2 to 10, 11 to
15, 16 to 20, and 21 and higher. The highest two risk
groups together contained 77% (110/143) of all micro-
albuminuric patients of the development set and 79%, 80%
and 84% of all microalbuminuric patients of the validation
sets. We would advocate offering these high-risk patients
more frequent check-ups than once a year, perhaps together
with the quarterly routine visit and with an overnight or
24 h urine collection to measure the albumin:creatinine
ratio. Current surveillance protocols recommend follow-up
of patients more frequently than once a year only after an
abnormal surveillance result. Under this protocol, a consid-
erable proportion of new microalbuminuria cases will be
recognised later than necessary. The identification, by our
prediction rule, of a group of patients with normal AER and
at high risk of progressing to microalbuminuria might
facilitate the early introduction of ACE inhibitor or
angiotensin receptor blocker therapy, if trials currently
under way suggest benefit. Glycaemic control could also
be intensified and other risk factors for microalbuminuria,
e.g. smoking, BMI and WHR could be more strictly
controlled than is usual. It is currently unknown whether
such intervention strategies based on our prediction rule
would be of benefit; this should be the focus of future
research.
Unfortunately, the model predicts for one occasion only,
i.e. after 7 years offollow-up. The assessment of the outcome
only after 7 years has two implications. First, we do not have
information on time of onset of microalbuminuria. Time-to-
event analysis, e.g. with Cox proportional hazards regression
analysis, was therefore not possible. Second, we do not know
how many patients remain microalbuminuric and how many
regress. Several studies have shown regression of micro-
albuminuria in type 1 diabetes patients [2, 27, 28].
Cumulative incidences of regression vary between 13%
and 56% and are mainly induced by intensive therapy. Only
few patients with microalbuminuria undergo spontaneous
regression that is permanent (around 15%) [2]. Consequent-
ly, our rule may only slightly overestimate a patient’s risk of
progression to microalbuminuria.
In conclusion, we developed a prediction rule to estimate
the risk of progressing to microalbuminuria in individual
type 1 diabetes patients. The rule was developed in a
European cohort and externally validated in two US cohorts
and another European cohort. We believe that this predic-
tion rule could be used to divide patients into different risk
categories. Such risk categories could guide surveillance
recommendations and ultimately improve the prevention of
long-term chronic complications.
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